+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Clostridium Difficile Treatment Market by Treatment Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Clostridium Difficile Treatment Market by Treatment Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030- Product Image
Sale

Clostridium Difficile Treatment Market by Treatment Type, Route of Administration, Distribution Channel, End User - Global Forecast to 2030

  • PDF Icon

    Report

  • 199 Pages
  • May 2025
  • Region: Global
  • 360iResearch™
  • ID: 6014676
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Clostridium Difficile Treatment Market grew from USD 9.41 billion in 2024 to USD 10.07 billion in 2025. It is expected to continue growing at a CAGR of 6.94%, reaching USD 14.08 billion by 2030.

Framing the Clostridium difficile Challenge with Strategic Clarity

Clostridium difficile continues to pose a significant challenge across healthcare settings, leading to increased patient morbidity and economic strain on providers worldwide. The pathogen’s resilience and propensity for recurrence have driven the need for more sophisticated treatment paradigms beyond traditional antibiotic regimens. As incidence rates rise and resistance patterns shift, stakeholders must adopt a holistic view that encompasses therapeutic efficacy, safety profiles, and overall patient journey.

This executive summary distills critical insights from a multifaceted analysis of current and emerging interventions. Drawing on policy developments, clinical innovations, and supply chain dynamics, it offers a clear lens through which decision-makers can anticipate market shifts and refine strategic priorities. The goal is to lay a foundation for transformative action in combating C. difficile infection and shaping a patient-centric standard of care.

Emerging Paradigms Reshaping Treatment and Patient Outcomes

The treatment landscape for Clostridium difficile is undergoing profound transformation driven by breakthroughs in microbiome science and biologic therapies. Where once broad-spectrum antibiotics reigned supreme, targeted monoclonal antibodies and preventative vaccines now disrupt the status quo. Concurrently, the advent of synthetic microbiota restoration therapies promises to recalibrate gut ecosystems with precision, offering durable protection against relapse.

Advances in diagnostic technologies further accelerate this shift by enabling real-time strain identification and resistance profiling. Point-of-care molecular assays, coupled with data-driven risk models, empower clinicians to tailor regimens and minimize collateral damage to the native microbiome. These converging trends mark a departure from one-size-fits-all approaches and usher in an era of personalized, ecosystem-oriented care.

Regulatory frameworks have responded to this momentum by expediting pathways for breakthrough therapies and supporting post-market surveillance. As investment flows into both early-stage research and late-phase clinical trials, the sector is poised for sustained growth and continuous innovation.

Navigating the 2025 Tariff Landscape and Its Ripple Effects

The introduction of targeted tariffs on imported pharmaceuticals in 2025 has reverberated across the Clostridium difficile treatment continuum. As dependencies on international manufacturing hubs for key biologics and specialized formulations became apparent, stakeholders grappled with elevated procurement costs and disrupted timelines. These shifts have placed renewed emphasis on cost containment strategies and localization of production to mitigate future exposure to policy fluctuations.

Pharmaceutical developers and healthcare systems have responded by diversifying supply chains and forging strategic alliances with domestic manufacturers. This realignment has alleviated some pricing pressures for intravenous antibiotics and high-value biologic therapies, while stimulating investment in in-country facilities for microbiota restoration products. Payers, in turn, have revisited reimbursement frameworks to accommodate the evolving cost structure, balancing affordability with the imperative to sustain innovation.

Looking ahead, a proactive approach to tariff risk management-including scenario planning and continuous monitoring of trade policies-will be essential. Entities that master these dynamics can safeguard patient access and reinforce market resilience.

Segmented Perspectives Driving Specialized Therapeutic Adoption

The treatment landscape is stratified across primary therapy classes, each encompassing distinct modalities and clinical objectives. First, antibiotics serve as the cornerstone of initial intervention, with formulations delivered intravenously in acute settings and orally during ambulatory care. Next, biologic solutions offer targeted neutralization of toxins or priming of immune defenses, with monoclonal antibodies and vaccine candidates advancing through diverse regulatory stages. Finally, microbiota restoration therapies aim to restore gut homeostasis, whether through traditional fecal microbiota transplantation or emerging synthetic consortia designed for enhanced safety and consistency.

Route of administration further refines these categories, spotlighting the operational and adherence considerations inherent in intravenous infusion versus oral dosing. Distribution channels span the full spectrum of modern pharmaceutical delivery, from hospital-based pharmacies through online dispensaries to community retail outlets. This multifaceted structure underscores the importance of channel optimization and patient convenience in driving uptake.

Across care settings, the end-user environment ranges from ambulatory surgical facilities and outpatient clinics to acute care hospitals and long-term care institutions. Each venue presents unique procedural workflows, reimbursement pathways, and stakeholder priorities, demanding tailored engagement strategies and educational initiatives.

Regional Dynamics Influencing Treatment Accessibility and Uptake

Geographic variation in treatment patterns reflects diverse healthcare infrastructures and policy landscapes. In the Americas, robust clinical trial networks and established reimbursement systems have accelerated adoption of both biologics and microbiota restoration therapies. Patient advocacy and digital health integration have further catalyzed growth, particularly in regions with centralized care models.

Across Europe, the Middle East and Africa, regulatory harmonization efforts have streamlined cross-border approvals, fostering a competitive environment for novel vaccines and monoclonal antibody platforms. Public health agencies in these regions are increasingly prioritizing post-treatment surveillance and antimicrobial stewardship, reinforcing the role of advanced diagnostics.

In the Asia-Pacific arena, rapid hospital network expansion and rising healthcare expenditure have created fertile ground for market entry. Emerging economies within this region are bolstering infrastructure to support intravenous therapies, while metropolitan centers pioneer telemedicine initiatives that enhance outpatient management and patient follow-up.

Competitive Landscape and Pioneers Driving Innovation

Innovation leaders are defining the competitive frontier through robust pipelines and strategic partnerships. Legacy pharmaceutical firms have leveraged extensive R&D capabilities to bring next-generation antibiotics to late-stage development, while biotech pioneers focus on synthetic microbiome platforms that promise scalability and regulatory clarity. Vaccine developers are mobilizing global trial networks to validate prophylactic approaches, challenging conventional post-infection paradigms.

Collaborations between academic centers and industry players have yielded accelerated translational efforts, particularly in the domain of toxin-binding biologics. Meanwhile, digitally native health technology companies are introducing diagnostic and monitoring solutions that seamlessly integrate into clinical workflows, strengthening evidence generation and patient engagement.

As market leaders refine their portfolios, attention is shifting toward lifecycle management, with targeted investments in real-world evidence studies and patient assistance programs designed to optimize both uptake and long-term adherence.

Strategic Imperatives for Leaders in C. difficile Care

Industry leaders must adopt forward-looking strategies to capture emerging opportunities and mitigate evolving risks. They should prioritize investment in next-generation microbiota therapies, harnessing synthetic consortia to deliver predictable safety and efficacy. Concurrently, strengthening supply chain resilience through dual sourcing and localized manufacturing will be critical to offset tariff volatility.

Engaging payers early to shape evidence requirements and reimbursement pathways will enhance market access. Leveraging real-world data platforms and digital adherence tools can generate the granular outcomes that support value-based contracting models. Organizations should also forge cross-sector partnerships, uniting academic, biotech, and diagnostic experts to accelerate holistic solutions.

Finally, fostering a culture of continuous learning-through clinician education, patient outreach, and iterative feedback loops-will ensure adaptive excellence. By embracing these imperatives, decision-makers can drive sustainable growth and deliver superior patient outcomes in the dynamic C. difficile arena.

Rigorous Framework Underpinning Comprehensive Analysis

This analysis is grounded in a rigorous, mixed-methodology framework designed to ensure both breadth and depth of insight. Primary research included structured interviews with healthcare practitioners, payers, and industry executives, providing real-time perspectives on clinical adoption and reimbursement trends. Secondary sources encompassed peer-reviewed journals, regulatory filings, and company disclosures, facilitating comprehensive cross-validation of therapeutic advancements and policy developments.

Quantitative assessments drew upon proprietary databases and public health registries to map treatment utilization patterns and supply chain configurations. Multiple layers of triangulation were applied to reconcile data discrepancies and enhance analytical fidelity. Findings were subjected to expert panel review, incorporating feedback from leading microbiologists, gastroenterologists, and health economists to refine strategic narratives.

This robust approach ensures that the conclusions and recommendations presented herein rest on a foundation of verifiable evidence, contemporary stakeholder input, and industry best practices.

Synthesizing Insights to Chart Future Treatment Pathways

The evolving Clostridium difficile treatment landscape presents a confluence of innovation and complexity. Emerging biologics and microbiome therapies challenge traditional antibiotic paradigms, while tariff policies and supply chain realignments underscore the imperative for strategic agility. Segmented insights reveal differentiated pathways by therapy class, administration route, and care setting, and regional dynamics highlight both opportunities and barriers across diverse healthcare systems.

Competitive intensity is escalating as established firms and biotech disruptors vie for leadership through targeted R&D and strategic alliances. To thrive, organizations must align evidence generation with payer expectations, invest in localized manufacturing, and harness digital platforms for outcome measurement. The recommendations outlined in this executive summary offer a roadmap for navigating these dimensions and achieving lasting impact.

In synthesis, a proactive, integrated approach-anchored in robust data and collaborative innovation-will be essential to advance patient care and secure sustainable growth in the C. difficile domain.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Treatment Type
    • Antibiotics
      • Intravenous Antibiotics
      • Oral Antibiotics
    • Biologics
      • Monoclonal Antibodies
      • Vaccines
    • Microbiota Restoration Therapy
      • Fecal Microbiota Transplantation
      • Synthetic Microbiota Therapy
  • Route Of Administration
    • Intravenous
    • Oral
  • Distribution Channel
    • Hospital Pharmacy
    • Online Pharmacy
    • Retail Pharmacy
  • End User
    • Ambulatory Surgical Centers
    • Clinics
    • Hospitals
    • Long Term Care Facilities
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report categorizes to delves into recent significant developments and analyze trends in each of the following companies:
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Takeda Pharmaceutical Company Limited
  • Amneal Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Ferring Pharmaceuticals A/S
  • Hikma Pharmaceuticals PLC
  • Seres Therapeutics, Inc.

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Clostridium Difficile Treatment Market, by Treatment Type
8.1. Introduction
8.2. Antibiotics
8.2.1. Intravenous Antibiotics
8.2.2. Oral Antibiotics
8.3. Biologics
8.3.1. Monoclonal Antibodies
8.3.2. Vaccines
8.4. Microbiota Restoration Therapy
8.4.1. Fecal Microbiota Transplantation
8.4.2. Synthetic Microbiota Therapy
9. Clostridium Difficile Treatment Market, by Route of Administration
9.1. Introduction
9.2. Intravenous
9.3. Oral
10. Clostridium Difficile Treatment Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
11. Clostridium Difficile Treatment Market, by End User
11.1. Introduction
11.2. Ambulatory Surgical Centers
11.3. Clinics
11.4. Hospitals
11.5. Long Term Care Facilities
12. Americas Clostridium Difficile Treatment Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Clostridium Difficile Treatment Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Clostridium Difficile Treatment Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Merck & Co., Inc.
15.3.2. Teva Pharmaceutical Industries Ltd.
15.3.3. Sandoz International GmbH
15.3.4. Viatris Inc.
15.3.5. Takeda Pharmaceutical Company Limited
15.3.6. Amneal Pharmaceuticals, Inc.
15.3.7. Dr. Reddy's Laboratories Ltd.
15.3.8. Ferring Pharmaceuticals a/S
15.3.9. Hikma Pharmaceuticals PLC
15.3.10. Seres Therapeutics, Inc.
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. CLOSTRIDIUM DIFFICILE TREATMENT MARKET MULTI-CURRENCY
FIGURE 2. CLOSTRIDIUM DIFFICILE TREATMENT MARKET MULTI-LANGUAGE
FIGURE 3. CLOSTRIDIUM DIFFICILE TREATMENT MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 12. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 14. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. CLOSTRIDIUM DIFFICILE TREATMENT MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. CLOSTRIDIUM DIFFICILE TREATMENT MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY INTRAVENOUS ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ORAL ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY VACCINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY FECAL MICROBIOTA TRANSPLANTATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY SYNTHETIC MICROBIOTA THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY LONG TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 36. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 37. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 38. AMERICAS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 39. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 40. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 41. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 42. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 47. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 48. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 49. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 50. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 51. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 52. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 53. CANADA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 54. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 55. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 56. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 57. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 58. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 59. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 60. MEXICO CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 63. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 64. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 65. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 66. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 67. BRAZIL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 75. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 76. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 77. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 78. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 79. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 80. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 81. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 82. EUROPE, MIDDLE EAST & AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 83. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 84. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 85. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 86. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 87. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 88. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 89. UNITED KINGDOM CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 90. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 91. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 92. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 93. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 94. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 95. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 96. GERMANY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 97. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 98. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 99. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 100. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 101. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 103. FRANCE CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 104. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 105. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 106. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 107. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 108. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 109. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 110. RUSSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 111. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 112. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 113. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 114. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 115. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 116. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 117. ITALY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 119. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 120. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 121. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 122. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 123. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 124. SPAIN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 125. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 126. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 127. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 128. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 129. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 130. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 131. UNITED ARAB EMIRATES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 132. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 133. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 134. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 135. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 136. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 137. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 138. SAUDI ARABIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 140. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 141. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 142. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 143. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 144. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 145. SOUTH AFRICA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 146. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 147. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 148. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 149. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 150. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 151. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 152. DENMARK CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 153. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 154. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 155. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 156. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 157. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 159. NETHERLANDS CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 160. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 161. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 162. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 163. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 164. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 165. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 166. QATAR CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 167. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 168. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 169. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 170. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 171. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 172. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 173. FINLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 175. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 176. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 177. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 178. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 179. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 180. SWEDEN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 181. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 182. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 183. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 184. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 185. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 186. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 187. NIGERIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 188. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 189. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 190. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 191. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 192. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 194. EGYPT CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 195. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 196. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 197. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 198. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 199. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 200. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 201. TURKEY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 204. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 205. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 206. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 207. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 208. ISRAEL CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 210. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 211. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 212. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 213. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 214. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 215. NORWAY CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 216. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 217. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 218. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 219. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 220. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 221. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 222. POLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 224. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 225. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 226. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 227. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 229. SWITZERLAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 230. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 231. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 232. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 233. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 234. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 235. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 236. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 237. ASIA-PACIFIC CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 238. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 239. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 240. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 241. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 242. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 243. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 244. CHINA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 245. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 246. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 247. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 248. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 249. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 250. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 251. INDIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 252. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 253. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 254. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 255. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 256. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 257. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 258. JAPAN CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 259. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 260. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 261. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 262. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 263. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 264. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 265. AUSTRALIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 266. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 267. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 268. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 269. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 270. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 271. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 272. SOUTH KOREA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 273. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 274. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 275. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 276. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 277. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 278. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 279. INDONESIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 280. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 281. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 282. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 283. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 284. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 285. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 286. THAILAND CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 287. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 288. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 289. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 290. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY MICROBIOTA RESTORATION THERAPY, 2018-2030 (USD MILLION)
TABLE 291. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 292. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
TABLE 293. PHILIPPINES CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 294. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY TREATMENT TYPE, 2018-2030 (USD MILLION)
TABLE 295. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
TABLE 296. MALAYSIA CLOSTRIDIUM DIFFICILE TREATMENT MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
TABLE 297. MAL

Companies Mentioned

The companies profiled in this Clostridium Difficile Treatment market report include:
  • Merck & Co., Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Sandoz International GmbH
  • Viatris Inc.
  • Takeda Pharmaceutical Company Limited
  • Amneal Pharmaceuticals, Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Ferring Pharmaceuticals A/S
  • Hikma Pharmaceuticals PLC
  • Seres Therapeutics, Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages199
PublishedMay 2025
Forecast Period2025 - 2030
Estimated Market Value ( USD ) in 2025 $ 10.07 Billion
Forecasted Market Value ( USD ) by 2030 $ 14.08 Billion
Compound Annual Growth Rate6.9%
Regions CoveredGlobal
No. of Companies Mentioned11

Related Topics

Related Reports

Clostridium Difficile Infections-Clostridium Difficile Associated Disease-Pipeline Insight, 2025 - Product Image

Clostridium Difficile Infections-Clostridium Difficile Associated Disease-Pipeline Insight, 2025

  • Clinical Trials
  • 80 Pages
  • Global
From
Clostridium Difficile Treatment - Global Strategic Business Report - Product Image

Clostridium Difficile Treatment - Global Strategic Business Report

  • Report
  • 192 Pages
  • Global
From
Clostridium Difficile Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type - Product Image

Clostridium Difficile Treatment Global Market Insights 2024, Analysis and Forecast to 2029, by Manufacturers, Regions, Technology, Application, Product Type

  • Report
  • 100 Pages
  • Global
From
Multidrug Resistant Bacteria Market Report 2025 - Product Image

Multidrug Resistant Bacteria Market Report 2025

  • Report
  • 200 Pages
  • Global
From
The Bacterial Spore. From Molecules to Systems. Edition No. 1. ASM Books - Product Image

The Bacterial Spore. From Molecules to Systems. Edition No. 1. ASM Books

  • Book
  • 397 Pages

About the Clostridium Difficile Drug Market

Clostridium Difficile (C. Difficile) is a type of bacteria that can cause severe diarrhea and other intestinal problems. It is a major cause of infectious diseases, and is particularly common in hospitals and nursing homes. Treatment for C. Difficile typically involves antibiotics, and the C. Difficile Drug market is focused on developing and marketing drugs to treat this infection. The C. Difficile Drug market is highly competitive, with many companies developing and marketing drugs to treat this infection. These drugs are typically used in combination with other treatments, such as probiotics, to reduce the risk of recurrence. Companies in the C. Difficile Drug market include Merck, Pfizer, GlaxoSmithKline, Sanofi, and AstraZeneca. Show Less Read more

Copyright © 2002-2025 Research and Markets. All Rights Reserved.